Stockreport

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

CG Oncology, Inc. - Common stock  (CGON) 
PDF PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 [Read more]